Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
54 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Retinoblastoma - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Retinoblastoma - Pipeline Review, H2 2014', provides an overview of the Retinoblastoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Retinoblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinoblastoma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Retinoblastoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Retinoblastoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Retinoblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Retinoblastoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Retinoblastoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Retinoblastoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Retinoblastoma Overview 6 Therapeutics Development 7 Pipeline Products for Retinoblastoma - Overview 7 Pipeline Products for Retinoblastoma - Comparative Analysis 8 Retinoblastoma - Therapeutics under Development by Companies 9 Retinoblastoma - Therapeutics under Investigation by Universities/Institutes 10 Retinoblastoma - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Retinoblastoma - Products under Development by Companies 13 Retinoblastoma - Products under Investigation by Universities/Institutes 14 Retinoblastoma - Companies Involved in Therapeutics Development 15 BioLineRx, Ltd. 15 Neotropix, Inc. 16 Cellceutix Corporation 17 Recombio S.L 18 Icon Bioscience, Inc. 19 RXi Pharmaceuticals Corporation 20 Retinoblastoma - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Target 22 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Drug Profiles 30 NTX-010 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 racotumomab - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Kevetrin - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 BL-8040 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 melphalan - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 RNAi Oligonucleotide for Retinoblastoma - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 nutlin-3 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Retinoblastoma - Recent Pipeline Updates 42 Retinoblastoma - Dormant Projects 50 Retinoblastoma - Product Development Milestones 51 Featured News & Press Releases 51 Mar 08, 2013: Cellceutix Announces Positive Preclinical Trial Data Of Kevetrin In Retinoblastoma 51 Jan 03, 2013: Icon's Melphalan Intraocular Injection Receives US Orphan Drug Designation For Treatment Of Retinoblastoma 51 Appendix 53 Methodology 53 Coverage 53 Secondary Research 53 Primary Research 53 Expert Panel Validation 53 Contact Us 54 Disclaimer 54
List of Tables Number of Products under Development for Retinoblastoma, H2 2014 7 Number of Products under Development for Retinoblastoma - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Number of Products under Investigation by Universities/Institutes, H2 2014 10 Comparative Analysis by Clinical Stage Development, H2 2014 11 Comparative Analysis by Early Stage Development, H2 2014 12 Products under Development by Companies, H2 2014 13 Products under Investigation by Universities/Institutes, H2 2014 14 Retinoblastoma - Pipeline by BioLineRx, Ltd., H2 2014 15 Retinoblastoma - Pipeline by Neotropix, Inc., H2 2014 16 Retinoblastoma - Pipeline by Cellceutix Corporation, H2 2014 17 Retinoblastoma - Pipeline by Recombio S.L, H2 2014 18 Retinoblastoma - Pipeline by Icon Bioscience, Inc., H2 2014 19 Retinoblastoma - Pipeline by RXi Pharmaceuticals Corporation, H2 2014 20 Assessment by Monotherapy Products, H2 2014 21 Number of Products by Stage and Target, H2 2014 23 Number of Products by Stage and Mechanism of Action, H2 2014 25 Number of Products by Stage and Route of Administration, H2 2014 27 Number of Products by Stage and Molecule Type, H2 2014 29 Retinoblastoma Therapeutics - Recent Pipeline Updates, H2 2014 42 Retinoblastoma - Dormant Projects, H2 2014 50
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.